


## **2025 Bladder & Kidney Cancer Academy Agenda**

Hilton BNA Nashville Airport  
2 Terminal Drive  
Nashville, TN 37214

### **Thursday, October 16, 2025**

10:00 AM	<b>Registration:</b> Attendees & Industry Sponsors	Gateway Ballroom Foyer
12:00 – 1:00 PM	<b>Attendee Lunch:</b> Merck <i>*Closed door session to only attendees &amp; Merck team members</i>	Gateway Ballroom DE, Lobby Level 
12:00 – 1:00 PM	<b>Industry &amp; Exhibitor Lunch</b>	Lindbergh + Earhart
1:00 – 1:10 PM	<b>Transition to General Session</b>	
1:10 – 1:30 PM	<b>Welcome:</b> 2025 Bladder & Kidney Cancer Academy	Neal Shore, MD, FACS <i>Medical Director, Carolina Urologic Research Center</i> <i>Atlantic Urology Urologists</i>  Tom Jayram, MD <i>Director, Advanced Therapeutics Center</i> <i>Urology Associates, PC</i>
1:30 – 1:45 PM	<b>Management of Small Renal Mass</b>	Robert Uzzo, MD, MBA, FACS <i>President &amp; Chief Executive Officer</i> <i>Fox Chase Cancer Center</i>
1:45 – 2:00 PM	<b>Novel Advances in RCC Imaging</b>	Robert Uzzo, MD, MBA, FACS
2:00 – 2:20 PM	<b>Pearls for the Kidney Cancer Surgeon</b>	Daniel Joyce, MD, MS <i>Assistant Professor</i> <i>Vanderbilt Health</i>
2:20 – 2:30 PM	<b>Industry Updates</b>	
2:30 – 3:10 PM	<b>Cases in Localized Kidney Cancer</b>	
3:10 – 3:45 PM	<b>Networking Break</b>	
3:45 – 4:00 PM	<b>Radiation Approaches to RCC</b>	Jason Efstathiou, MD, DPhil <i>Professor, Radiation Oncology</i> <i>Harvard Medical School</i>
4:00 – 4:15 PM	<b>Perioperative Approach to the High Risk RCC Patient</b>	Chandler Park, MD <i>Genitourinary Medical Oncology</i> <i>Norton Healthcare</i>
4:15 – 4:30 PM	<b>Surgical and Nonsurgical Management of UTUC</b>	Daniel Joyce, MD, MS

4:30 – 4:45 PM	<b>Industry Updates</b>	
4:45 – 5:15 PM	<b>Cases in Advanced Kidney Cancer</b>	<b>Panel:</b> Jason Efstathiou, MD, DPhil Daniel Joyce, MD, MS Chandler Park, MD
5:15 – 5:25 PM	<b>Thursday Closing Remarks:</b> Summary & Takeaways with Academy Co-Directors	Neal Shore, MD, FACS  Tom Jayram, MD
5:30 – 7:00 PM	<b>Welcome Reception</b> <i>*Sponsored by Ferring Pharmaceuticals</i>	Sky Pavilion
	 Uro-Oncology	
<b>Friday, October 17, 2025</b>		
7:00 AM	<b>Day 2 Begins</b>	
7:00 – 8:00 AM	<b>Attendee Breakfast:</b> Ferring <i>*Closed door session to only attendees &amp; Ferring team members</i>	Gateway Ballroom DE
	 Uro-Oncology	
7:00 – 8:00 AM	<b>Industry &amp; Exhibitor Breakfast</b>	Lindbergh + Earhart
8:00 – 8:10 AM	<b>Transition to General Session</b>	Gateway Ballroom ABC, Lobby Level
8:10 – 8:15 AM	<b>Welcome Back</b>	Neal Shore, MD, FACS  Tom Jayram, MD
8:15 – 8:30 AM	<b>Updates in Intermediate Risk NMIBC</b> - What to do in 2026	Max Kates, MD <i>Division Director, Urologic Oncology Johns Hopkins School of Medicine</i>
8:30 – 9:05 AM	<b>Evolution of BCG Naïve Treatment</b>	
8:30 – 8:45 AM	<b>CREST Overview</b>	Neal Shore, MD, FACS
8:45 – 8:55 AM	<b>Debate</b> – IO Should be Utilized in BCG Naïve HR NMIBC	Joshua Meeks, MD, PhD <i>Associate Professor, Urology, Biochemistry &amp; Molecular Genetics Northwestern Medicine</i>
8:55 – 9:05 AM	<b>Debate</b> – IO Should not be Utilized in BCG Naïve HR NMIBC	Vignesh Packiam, MD <i>Director, Clinical &amp; Translational Research in Urologic Oncology Rutgers Cancer Institute</i>
9:05 – 9:20 AM	<b>Updates in BCG Exposed/Unresponsive Disease</b>	Sam Chang, MD, MBA <i>Chief Surgical Officer Vanderbilt University Medical Center</i>

9:20 – 9:45 AM **Cases in BCG Unresponsive Disease**

**Moderator:**  
Tom Jayram, MD

**Panel:**  
Sam Chang, MD, MBA  
Joshua Meeks, MD, PhD  
Max Kates, MD

9:45 – 10:00 AM **Industry Updates**

10:00 – 10:35 AM	<b>Break:</b> Coffee & Networking with Exhibitors	Gateway Ballroom Foyer
10:35 – 10:45 AM	<b>BCG Updates</b> – Merck	
10:45 – 10:55 AM	<b>Overview of Recombinant BCG</b> – ImmunityBio	
10:55 – 11:10 AM	<b>PRIME &amp; BRIDGE</b> – What the Future Holds	Max Kates, MD
11:10 – 11:30 AM	<b>Contemporary Biomarkers in NMIBC</b>	Joshua Meeks, MD, PhD
11:30 – 11:45 AM	<b>Optimal Cystoscopy in 2026</b>	Vignesh Packiam, MD

11:45 AM – 12:00 PM **Industry Updates**

12:00 – 1:00 PM	<b>Attendee Lunch:</b> Johnson & Johnson <i>*Closed Session for Johnson &amp; Johnson &amp; Attendees</i>	Gateway Ballroom DE
-----------------	--	---------------------

**Johnson&Johnson**

12:00 – 1:00 PM **Industry & Exhibitor Lunch** Lindbergh + Earhart

1:00 – 1:05 PM	<b>Transition to General Session</b>	Gateway Ballroom ABC
1:05 – 1:25 PM	<b>Perioperative Systemic Therapy Strategies in MIBC</b>	Chandler Park, MD
1:30 – 1:45 PM	<b>Quality of Life Following Radical Cystectomy</b>	Sam Chang, MD, MBA
1:50 – 2:05 PM	<b>Advances in Radiation Therapy for Bladder Cancer</b>	Jason Efstathiou, MD, DPhil
2:10 – 2:20 PM	<b>Incorporating ctDNA into Treatment Decisions</b>	Joshua Meeks, MD, PhD
2:20 – 2:35 PM	<b>Systemic Approaches to Metastatic Disease</b>	Chandler Park, MD
2:35 – 3:10 PM	<b>MIBC Panel and Cases</b>	<b>Panel:</b> Sam Chang, MD, MBA Jason Efstathiou, MD, DPhil Joshua Meeks, MD, PhD Chandler Park, MD

3:15 – 3:30 PM **Industry Update**

3:30 – 4:00 PM	<b>Break:</b> Networking with Exhibitors	Gateway Ballroom Foyer
4:00 – 5:00 PM	<b>CME:</b> TBA	

5:00 – 5:15 PM

**Closing Ceremony:** Summary & Takeaways with BKCA  
Co-Directors

Neal Shore, MD, FACS

Tom Jayram, MD

5:15 – 6:30 PM

**Networking Reception**  
*\*Sponsored by Telix  
Pharmaceuticals*



Gateway Ballroom Foyer